Golimumab for the treatment of Hidradenitis Suppurativa

Published: 28 May 2021| Version 1 | DOI: 10.17632/fwjvy294wy.1
Contributor:
Christopher Sayed

Description

Golimumab for the Treatment of Hidradenitis Suppurativa

Files

Steps to reproduce

Subjects were identified with clinical tracking lists. Clinical data was pulled via chart review including lesion counts, demographics, disease severity, treatment duration and other clinical measures

Institutions

University of North Carolina at Chapel Hill School of Medicine

Categories

Tumor Necrosis Factor, Hidradenitis Suppurativa

Licence